Tag: Novoheart

Novoheart Contracts with Global Pharma to Develop Novel Microplate for High Throughput Drug Screening Using Engineered Human Heart Tissue Strips

New 96-Well Microplates (hvCTS-96) to Further Advance MyHeart™ Platform Capabilities for High-throughput Screening of Compounds on Engineered Human Heart Tissue Strips Novoheart Partners with a Global Pharma to Design and Develop the New Microplate and Will Retain Full Ownership of All IP Novoheart is to Enter a Billion-dollar Market and Generate […]

Continued Success of Novoheart to Receive R&D Grants: Innovation Technology Fund for Developing Smart Cardiac Screening Technologies

Grant will fund advanced R&D and incorporation of artificial intelligence (AI) technology to accelerate drug development using Novoheart’s bio-engineered human heart chambers and tissues The resulting advancements expected to increase scale and capabilities of Novoheart’s MyHeart™ Platform and expand commercialization opportunities for Novoheart’s market-leading technologies VANCOUVER, British Columbia, Jan. 07, […]

Novoheart Licenses Harvard Technology to Develop Next-Generation Human Heart-in-a-Jar

Novoheart engineered the world’s first “human heart-in-a-jar” as part of its proprietary MyHeart™ platform Novoheart receives exclusive license from Harvard University to integrate pioneering bioreactor technology that accommodates model ventricles and optional valves into the “human heart-in-a-jar” model The resultant next-generation model will have unparalleled biofidelity as well as enhanced […]

Novoheart Provides Corporate Update

VANCOUVER, British Columbia, Nov. 29, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announced today that Joseph Leung resigned as Chief Financial Officer and Corporate Secretary of the Company effective immediately. Ronald Li, Chief Executive Officer, stated, “On behalf of Novoheart, I would […]

Novoheart to Co-develop First of its Kind Human Heart-in-a-Jar Model of Heart Failure with AstraZeneca

Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year Drug developers currently lack effective humanized models for preclinical testing of targeted drug candidates in heart failure with preserved ejection fraction The collaboration aims to provide a unique solution for […]

Novoheart Holdings Inc. Reports First Quarter 2020 Financial Results

VANCOUVER, British Columbia, Nov. 19, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three months ended September 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). Q1 2020 BUSINESS HIGHLIGHTS […]

Novoheart Grants Stock Options

VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) (TSXV: NVH; FWB: 3NH) announces that it has granted incentive stock options to purchase an aggregate of 1,150,000 common shares of the Company (the “Options”) to non-executive directors of the Company. Option Grants The Options have […]

Two new Pfizer-coauthored studies validate Novoheart’s pioneering human bioengineered heart tissues and chambers for improving drug development

September 09, 2019 00:05 ET | Source: Novoheart Holdings Inc. Novoheart seeks to revolutionize human heart tissue engineering for disease modeling and drug discovery Peer-reviewed publications feature results from the completion of two research contracts between Novoheart and Pfizer Novoheart’s proprietary MyHeartTM Platform of human bioengineered heart tissues can represent healthy as well as […]

Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2019 Financial Results

VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). Ronald Li, […]